{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:31:24Z","timestamp":1761989484039,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lungcan.2020.07.013","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T12:04:37Z","timestamp":1596283477000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry"],"prefix":"10.1016","volume":"148","author":[{"given":"Ju-Yoon","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Quest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Pabedinskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prodipto","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Schwock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyang-Mi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2020.07.013_bib0005","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.3747\/co.25.3976","article-title":"Targeting the PD-1\/PD-L1 axis for the treatment of non-small-cell lung cancer","volume":"25","author":"Meyers","year":"2018","journal-title":"Curr. Oncol."},{"issue":"34","key":"10.1016\/j.lungcan.2020.07.013_bib0010","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer","volume":"35","author":"B\u00fcttner","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.013_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2020.07.013_bib0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"34","key":"10.1016\/j.lungcan.2020.07.013_bib0025","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer","volume":"35","author":"Buttner","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.013_bib0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000338169","article-title":"Pleural effusion in lung cancer: more questions than answers","volume":"83","author":"Froudarakis","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.lungcan.2020.07.013_bib0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2020.01.010","article-title":"Cytology for PD-L1 testing: a systematic review","volume":"141","author":"Gosney","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2020.07.013_bib0040","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/CVI.00259-09","article-title":"Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes","volume":"16","author":"Campbell","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.013_bib0045","doi-asserted-by":"crossref","first-page":"e0123410","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB","volume":"10","author":"Gowrishankar","year":"2015","journal-title":"PLoS One"},{"issue":"10183","key":"10.1016\/j.lungcan.2020.07.013_bib0050","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2020.07.013_bib0055","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2020.07.013_bib0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","article-title":"PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion","volume":"13","author":"Tseng","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.013_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ajcp\/109.1.85","article-title":"Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature","volume":"109","author":"Ordonez","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.013_bib0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","article-title":"Frequent EpCam protein expression in human carcinomas","volume":"35","author":"Went","year":"2004","journal-title":"Hum. Pathol."},{"issue":"Suppl. 56","key":"10.1016\/j.lungcan.2020.07.013_bib0075","first-page":"P4171","article-title":"EpCAM-positive circulating cells in lung cancer patients","volume":"40","author":"Domagala-Kulawik","year":"2012","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.013_bib0080","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.013_bib0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.013_bib0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.lungcan.2020.07.013_bib0095","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2020.07.013_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01337","article-title":"Recent findings in the regulation of programmed death ligand 1 expression","volume":"10","author":"Shen","year":"2019","journal-title":"Front. Immunol."},{"issue":"29","key":"10.1016\/j.lungcan.2020.07.013_bib0105","doi-asserted-by":"crossref","first-page":"20769","DOI":"10.18632\/oncotarget.25100","article-title":"Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2020.07.013_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","author":"Chapel","year":"2019","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.013_bib0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5858\/arpa.2019-0370-OA","article-title":"Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions","volume":"144","author":"Derakhshan","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2020.07.013_bib0120","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncy.21917","article-title":"Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining","volume":"125","author":"Mansour","year":"2017","journal-title":"Cancer Cytopathol."},{"issue":"Suppl_15","key":"10.1016\/j.lungcan.2020.07.013_bib0125","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.013_bib0130","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.2147\/CMAR.S176937","article-title":"Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis","volume":"11","author":"Ding","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.lungcan.2020.07.013_bib0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","article-title":"PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion","volume":"13","author":"Tseng","year":"2018","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:43:27Z","timestamp":1759236207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"alternative-id":["S0169500220305353"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.013","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}